QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 revenue of $618.9 million, down 12% year over year in constant currency, as China revenue fell 45% and Point of Care revenue declined 27%; adjusted EPS was $0.31 versus $0.80 a year earlier, and the company recorded a $53.8 million GAAP net loss. Management narrowed 2026 revenue guidance to $2.52 billion–$2.54 billion and expects China to contribute 4%–5% of revenue in 2027, versus about 8% in 2026. A restructuring is expected to deliver more than $80 million in annual savings in 2027, with $30 million–$35 million in charges expected in Q4 2026; net debt was about $2.8 billion and leverage was 4.5x.

Analysis

The key issue is earnings quality, not the headline savings target. Management says the >$80 million of savings is incremental and should more than offset the near-term China headwind, but the comparison is incomplete: China is shifting from inventory digestion to lower reimbursement pricing and stronger competition, while the savings ramp is weighted to the second half of 2027. Verify the revenue and gross-profit impact by product and province before treating the program as an earnings floor.

Near term, Q4 cash conversion faces a known hit from restructuring outflows, and Q3 adjusted gross margin benefited from roughly 300 bps of items not expected to recur. Thus, a cost-cut announcement could support the shares initially even as reported margins and free cash flow remain pressured. The covenant amendment reduces near-term financing risk, but does not itself improve the 4.5x leverage position; further weak EBITDA would make that flexibility less reassuring.

The counterweight is that ex-China labs and immunohematology growth and stable point-of-care share suggest the franchise is not uniformly deteriorating. The market may underappreciate that installed-base businesses can stabilize if placements and utilization hold. Conversely, capitalizing all promised savings before evidence of delivery risks overlooking restructuring execution, commercial disruption, and China mix deterioration. Over 6–18 months, the decisive tests are realized savings, China price/volume trends, and sustained—not working-capital- or capex-led—free cash flow.

Key Decisions for Investors

• Avoid buying QDEL solely on the restructuring announcement. Treat the shares as an event-driven watch until quarterly disclosures show realized savings and sustained free cash flow after restructuring payments.
• For an existing position, keep exposure modest and reassess after Q4 results. Falsifiers for the cautious thesis: savings ramping on schedule, China revenue stabilizing after provincial implementation, and recurring free cash flow improving without further capex reductions.
• If QDEL rallies materially on the savings narrative, consider a relative-value short in QDEL versus a diversified diagnostics peer such as Abbott or Danaher; size against the risk that core non-China growth and execution outweigh China pressure. No price or valuation data is supplied to set an entry level.
• Track China provincial pricing and order trends, Q4/Q1 gross margin excluding temporary benefits, restructuring cash costs, and net leverage. A further EBITDA decline or continued negative underlying cash generation would weaken the case that covenant capacity is merely precautionary.